updated 4/6/2010 2:03:35 PM ET 2010-04-06T18:03:35

The Food and Drug Administration has approved a new version of the painkiller OxyContin designed to be harder for patients to abuse, but one of the regulator's doctors said it may offer only "an incremental advantage."

  1. Don't miss these Health stories
    1. Splash News
      More women opting for preventive mastectomy - but should they be?

      Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.

    2. Larry Page's damaged vocal cords: Treatment comes with trade-offs
    3. Report questioning salt guidelines riles heart experts
    4. CDC: 2012 was deadliest year for West Nile in US
    5. What stresses moms most? Themselves, survey says

OxyContin treats severe chronic pain as a time-release version of the narcotic oxycodone. It is designed for use over 12 hours, to maintain a steady state of pain relief for seriously ill patients.

However, drug abusers quickly discovered they could get a heroin-like high by crushing the pills and snorting or injecting the dose. The new pill uses a coating designed to make the drug harder to crush and snort or inject.

The FDA's Monday decision follows a vote last fall by its panel of experts in favor of the reformulated drug, which is made by Purdue Pharma of Stamford, Conn.

"Although this new formulation of OxyContin may provide only an incremental advantage over the current version of the drug, it is still a step in the right direction," said Dr. Bob Rappaport in a statement from the FDA. Rappaport is director of the Division of Anesthesia and Analgesia Products in the FDA's Center for Drug Evaluation and Research.

Purdue Pharma will be required to study whether the new formulation of the drug reduces its abuse.

Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments